Cargando…
Changes and correlations of T-cell coinhibitory molecule programmed death-1 and interferon-γ in pediatric immune thrombocytopenia
BACKGROUND: Immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by abnormalities of T cells subsets. Programmed death-1 (PD-1) is a co-signaling inhibitory molecule in T cells that is involved in many autoimmune diseases. PURPOSE: Here we aimed to measure changes in PD-1 ex...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Pediatric Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989722/ https://www.ncbi.nlm.nih.gov/pubmed/36823790 http://dx.doi.org/10.3345/cep.2022.00920 |
Sumario: | BACKGROUND: Immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by abnormalities of T cells subsets. Programmed death-1 (PD-1) is a co-signaling inhibitory molecule in T cells that is involved in many autoimmune diseases. PURPOSE: Here we aimed to measure changes in PD-1 expression and serum interferon-γ (IFN-γ) levels before and 1 month after treatment in pediatric patients with newly diagnosed ITP. METHODS: We measured PD-1(+) CD4(+) T cells percentages using flow cytometry and the serum IFN-γ levels by enzyme-linked immunosorbent assay in 40 pediatric patients with ITP and 20 healthy controls. RESULTS: Compared with healthy controls, the PD-1(+) CD4(+) T cells percentages and serum IFN-γ levels were significantly higher in ITP patients before and 1 month after therapy. A correlation study revealed that PD-1(+) CD4(+) T cells percentage was negatively associated with platelet count and positively associated with IFN-γ level in patients with ITP. Furthermore, serum IFN-γ levels were significantly decreased in patients after treatment, but no significant change was detected in the percentage of PD-1(+) CD4(+) T cells before or 1 month after therapy. CONCLUSION: PD-1(+) CD4(+) T cells expression and IFN-γ levels were increased in patients with ITP. These preliminary data suggest a potential role of PD-1(+) CD4(+) T cells as mediators of ITP. We also found a correlation between PD-1(+) CD4(+) T cells and both platelet counts and IFN-γ levels. These findings suggest a potential role of PD-1(+) CD4(+) T cells and IFN-γ in the pathogenesis of ITP. Further studies investigating PD-1 expression in different T-cell subsets, serum IFN-γ concentrations, and antiplatelet antibodies levels over a longer duration after therapy initiation could delineate the precise role of PD-1 in ITP pathogenesis. Consequently, novel nontraditional therapeutic strategies for ITP patients may become available. |
---|